Know Cancer

forgot password

A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer

Phase 1/Phase 2
18 Years
Not Enrolling
Non Small Cell Lung Cancer

Thank you

Trial Information

A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer

The primary purpose of Part I of this study was to determine the maximum dose of perifosine
that can be administered with tolerable gastrointestinal toxicity; and to obtain preliminary
information on the response rate of perifosine in non-small cell lung cancer. In addition,
the trial was and is designed to provide some insight into the nature of the anti-tumor
effect, the time to response, and dose-schedules that should be used in future trials.

Part 2 - In the second part of this study, patients will be randomized to one of 3
dose-schedules of perifosine and to test if the response rate of perifosine in non small
cell lung cancer is > 10% in any of the 3 arms of the study. The study is not designed to
compare the response rates in the 3 arms of the trial, but toxicities will be compared.
The regimens are:

- A weekly dose of 900 mg to be divided into three doses of 300 mg each. If patients
experience no grade 2 toxicities during their first month of therapy, the dose will be
escalated to 1,200 mg divided into four doses of 300 mg.

- A daily dose of 150 mg to be divided into three doses of 50 mg each. If patients
experience no grade 2 toxicities during their first month of therapy, the dose will be
escalated to 200 mg divided into four doses of 50 mg.

- A daily dose of 150 mg to be given in one dose at bedtime. If patients experience no
grade 2 toxicities during their first month of therapy, the dose will be escalated to
200 mg to be given in one dose at bedtime.

Patients receiving weekly perifosine will receive prophylactic antiemetics. Patients
receiving daily perifosine will not routinely receive prophylactic antiemetics unless they
experience nausea. All patients may continue therapy unless disease progression is
documented on two occasions at least 4 weeks apart. Patients who experience toxicity may
continue on treatment with doses delayed or reduced.

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed diagnosis of non-small
cell lung cancer, must have progressed despite standard therapy and must not be
candidates for surgical or combined modality therapy.

- At least 18 years of age.

- Patients should have received at least one but no more than two prior chemotherapy
regimens for metastatic disease. The study chairman or medical monitor will consider
extenuating circumstances for patients with more than two such regimens.

- Patients must have measurable disease. Since the outcome for a patient is to be
based on response using RECIST criteria, the patient must have at least one
measurable lesion that can be accurately measured in at least one dimension and fit
one of the following criteria: longest diameter 20 mm using conventional techniques
or 10 mm with spiral CT scan.

- Patients must have a life expectancy of more than 3 months.

- Patients should have a performance status of 0 to 1 according to the ECOG criteria.
However, patients with ECOG performance status of 2 may be admitted with approval
from the study chairman or medical monitor.

- Female patients who are pregnant or lactating are ineligible. All females of
childbearing potential must have a negative serum pregnancy test within 72 hours of
treatment. Men and women of childbearing potential must agree to employ adequate
contraception to prevent pregnancy while on therapy and for four weeks after the
completion of treatment.

- Patients must have ability to understand and the willingness to sign a written
informed consent document.

Exclusion Criteria

- Patients with rapidly progressing disease, as defined by progression within 12 weeks
of initiation of the previous regimen.

- Patients receiving any other investigational agents or devices.

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to perifosine (miltefosine or edelfosine).

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection and psychiatric illness/social situations that would limit compliance with
study requirements.

- HIV-positive patients receiving combination anti-retroviral therapy are excluded from
the study because of possible pharmacokinetic interactions with perifosine.

- Patients with a history of unstable or newly diagnosed angina pectoris, recent
myocardial infarction (within 6 months of enrollment) or New York Heart Assoc. class
II-IV congestive heart failure.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Gastrointestinal toxicity of 3 different dose-schedules

Outcome Time Frame:

4 weeks

Safety Issue:


Principal Investigator

David Spigel, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Sarah Cannon Research Institute


United States: Food and Drug Administration

Study ID:

Perifosine 201



Start Date:

September 2004

Completion Date:

December 2011

Related Keywords:

  • Non Small Cell Lung Cancer
  • Non-Small-Cell Lung
  • Perifosine
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms



AOI Pharmaceuticals Investigative Site Berkeley, California  94704
AOI Pharmaceuticals Investigative Site Atlanta, Georgia  30322
AOI Pharmaceuticals Investigative Site Chicago, Illinois  60611
AOI Pharmaceuticals Investigative Site Ann Arbor, Michigan  48103
AOI Pharmaceuticals Investigative Site Orlando, Florida  32804
AOI Pharmaceuticals Investigative Site Greenville, South Carolina  29605
AOI Pharmaceuticals Investigative Site Dallas, Texas  75246
AOI Pharmaceuticals Investigative Site Tuscon, Arizona  85704
AOI Pharmaceuticals Investigative Site Billings, Montana  59103
AOI Pharmaceuticals Investigative Site Albany, New York  12208
AOI Pharmaceuticals Investigative Site Chattanooga, Tennessee  37404
AOI Pharmaceuticals Investigative Site New Albany, Indiana  47150
AOI Pharmaceuticals Investigative Site Albuquerque, New Mexico  87109